LINC 2023: Late-breaking Science Video Collection

Published: 20 June 2023

  • Views:

    Views Icon 773
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.

About the episode

LINC 23 - Dr Scott Trerotola (Penn Medicine, Philadelphia, PA, US) joins us to discuss the interim findings of the AVPAS Lutonix drug-coated balloon post-approval study.

The Lutonix 035 drug-coated balloon PTA catheter is a low-profile DCB designed to address de novo, restenotic or in-stent restenotic lesions in the superficial femoral and popliteal arteries. Dr Trerotola provides an insight into a prospective, global, multicenter post-approval study into the clinical use and safety of the Lutonix PTA catheter in patients with arteriovenous fistulae in the upper extremity.

Results suggest that this planned interim analysis of 81 patients shows a 6-month target lesion primary patency of 77.6%. 


  1. What is the reasoning behind this post-approval study?
  2. Tell us about the Lutonix PTA Catheter and its unique features.
  3. What were the study design and patient population?
  4. What were the key findings revealed at LINC 23?
  5. How should these findings impact clinical practice and future research?
  6. What further study is needed?

Recorded remotely from Philadelphia, 2023.
Interviewer: Jordan Rance
Video Specialist: Oliver Miles

Faculty Biographies

Scott O Trerotola

Scott O Trerotola

Associate Chair and Chief, Interventional Radiology

View full profile


You must be to comment. If you are not registered, you can register here.